EXEL vs TMDX
Exelixis vs TransMedics Group, Inc. — AI-powered side-by-side comparison
VS
TMDX
TransMedics Group, Inc.
60
Buy
| Metric | EXEL | TMDX |
|---|
| AI Score |
67
|
60
|
| Price |
$51.30
|
$89.39
|
| P/E Ratio |
15.60×
|
20.22×
|
| ROE |
36.2%
|
40.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
58.7%
|
| Debt / Equity |
0.09×
|
1.68×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.0
|
76.9
|
| Beta |
0.422
|
1.88
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus TMDX.
EXEL leads by 7 points.
EXEL scores 67/100 (Buy) versus TMDX at 60/100 (Buy).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
TMDX Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 25.8% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 26.6% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 33.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 25.8% YoY -- genuine top-line momentum — Growth
- EPS growing 105.5% YoY — Growth
Bear Case
- Price-to-book of 8.8x prices in significant intangible value — Value
- RSI at 77 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical